A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder
CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm
About this trial
This is an interventional treatment trial for CDKL5 Deficiency Disorder
Eligibility Criteria
Inclusion Criteria:
- Subject has a confirmed pathogenic or likely pathogenic mutation in the CDKL5 gene and a clinical diagnosis of CDD with epilepsy onset in the first year of life, plus motor and developmental delays.
- Subject is male or female, aged 1 to 35 years, inclusive, as of the day of the Screening Visit.
- Subject must have failed to achieve seizure control despite previous or current use of 2 or more AETs.
- Subject is currently receiving at least 1 concomitant antiseizure treatment: antiseizure medication (ASM), vagus nerve stimulation (VNS), responsive neurostimulation (RNS), or ketogenic diet (KD).
- All medications or interventions for epilepsy (including VNS, RNS, and KD) must be stable prior to screening and are expected to remain stable throughout the study.
- At the Screening Visit, parent/caregiver reports that subject has ≥ 4 countable motor seizures(CMS) per week.
Exclusion Criteria:
- Subject has a known hypersensitivity to fenfluramine or any of the excipients in the study drug.
- Subject has a diagnosis of pulmonary arterial hypertension.
- Subject has a clinically significant medical condition, including chronic obstructive pulmonary disease, interstitial lung disease, or portal hypertension, or has had clinically relevant symptoms or a clinically significant illness currently or in the 4 weeks prior to the Screening Visit, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the subject.
- Subject has current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke, severe ventricular arrhythmias, or clinically significant structural cardiac abnormality, including but not limited to mitral valve prolapse, atrial or ventricular septal defects, patent ductus arteriosus, and patent foramen ovale with reversal of shunt. (Note: Patent foramen ovale or a bicuspid aortic valve are not considered exclusionary).
- Subject has moderate to severe hepatic impairment.
- Subject has current eating disorder that suggests anorexia nervosa or bulimia.
- Subject has a current or past history of glaucoma.
- Subject is taking > 4 concomitant ASMs. Rescue medications are not included in the count.
- Subject is receiving concomitant treatment with cannabidiol (CBD) other than Epidiolex/Epidyolex or is being actively treated with tetrahydrocannabinol (THC) or any marijuana product for any condition.
- Subject has participated in another interventional clinical trial within 30 days of the Screening Visit or is currently receiving an investigational product.
- Subject has previously been treated with Fintepla® (fenfluramine) prior to the Screening Visit.
Sites / Locations
- Ep0216 122
- Ep0216 144Recruiting
- Ep0216 130Recruiting
- Ep0216 101Recruiting
- Ep0216 165Recruiting
- Ep0216 151Recruiting
- Ep0216 113Recruiting
- Ep0216 134Recruiting
- Ep0216 136Recruiting
- Ep0216 109Recruiting
- Ep0216 118Recruiting
- Ep0216 166Recruiting
- Ep0216 133Recruiting
- Ep0216 164Recruiting
- Ep0216 124Recruiting
- Ep0216 153Recruiting
- Ep0216 171Recruiting
- Ep0216 126Recruiting
- Ep0216 125Recruiting
- Ep0216 804Recruiting
- Ep0216 902Recruiting
- Ep0216 909Recruiting
- Ep0216 1512Recruiting
- Ep0216 1505Recruiting
- Ep0216 1502Recruiting
- Ep0216 1518Recruiting
- Ep0216 1401Recruiting
- Ep0216 2104Recruiting
- Ep0216 2105Recruiting
- Ep0216 1117Recruiting
- Ep0216 604Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Placebo Comparator
Experimental
ZX008 0.8 mg/kg/day
Placebo
ZX008
Part 1: ZX008 0.8 mg/kg/day will be administered twice a day (BID) in equally divided doses; maximum of 30 mg/day, (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, [maximum of 20 mg/day]) with or without food.
Part 1: Matching ZX008 placebo will be administered twice a day (BID) in equally divided doses with or without food.
Part 2: Open-label ZX008 will be administered using a flexible dosing regimen, up to ZX008 0.8 mg/kg/day; maximum dose: 30 mg/day (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, [maximum of 20 mg/day]). ZX008 will be administered twice a day (BID) in equally divided doses with or without food.